M. Idzko (Wien, Austria), C. Taube (Essen, Germany)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Follicular T helper and Breg cell balance in severe allergic asthma before and after omalizumab therapy
L. Bergantini (siena, Italy), M. D'Alessandro (siena, Italy), P. Cameli (siena, Italy), B. Cekorja (siena, Italy), E. Bargagli (siena, Italy)
|    |
The expression of IL17RA (the common subunit of IL-17A and IL-25 receptor) on sputum macrophages in asthma patients
P. Nejman-Gryz (Warsaw, Poland), M. Paplinska-Goryca (Warsaw, Poland), M. Proboszcz (Warsaw, Poland), E. Grabczak (Warsaw, Poland), J. Hermanowicz-Salamon (Warsaw, Poland), R. Krenke (Warsaw, Poland)
| |
IL-4Ra signaling is required for thymic stromal lymphopoietin (TSLP)-induced type 2 airway inflammation
S. Srivatsan (Tarrytown, United States of America), G. Scott (Tarrytown, United States of America), D. Birchard (Tarrytown, United States of America), J. Allinne (Tarrytown, United States of America), L. Ben (Tarrytown, United States of America), A. Murphy (Tarrytown, United States of America), M. Sleeman (Tarrytown, United States of America), J. Orengo (Tarrytown, United States of America)
| |
Clinical consequences and longitudinal outcomes in PiMZ heterozygous a1-antitrypsin deficiency smokers from SPIROMICS
I. Barjaktarevic (Los Angeles, United States of America), A. Manichaikul (Charlottsville, United States of America), D. Markovic (Los Angeles, United States of America), R. Hixson (Los Angeles, United States of America), C. Cooper (Los Angeles, United States of America), R. Buhr (Los Angeles, United States of America), R. Barr (New York, United States of America), J. Curtis (Ann Arbor, United States of America), M. Drummond (Chapell Hill, United States of America), S. Fortis (Iowa City, United States of America), G. Hawkins (Winston-Salem, United States of America), M. Han (Ann Arbor, United States of America), E. Hoffman (Iowa City, United States of America), V. Kim (Philadelphia, United States of America), X. Li (Tucson, United States of America), F. Martinez (Ithaca, United States of America), R. Paine Iii (Salt Lake City, United States of America), C. Pirozzi (Salt Lake City, United States of America), D. Tashkin (Los Angeles, United States of America), J. Wells (Birmingham, United States of America), P. Woodruff (San Francisco, United States of America), D. Meyers (Tucson, United States of America), E. Bleecker (Tucson, United States of America), V. Ortega (Winston-Salem, United States of America)
| |
A Reduced Frequency of GARPFoxp3 T Regulatory Cells in COPD Patients is Associated with Emphysema Phenotype
J. Hou (Yinchuan, China), X. Duan (Yinchuan, China), H. Li (Yinchuan, China), X. Zheng (Yinchuan, China)
|  |
Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST
A. Papi (Ferrara, Italy), K. Chapman (Toronto, Canada), M. Castro (Kansas City, KS, United States of America), D. Jackson (Madison, WI, United States of America), N. Daizadeh (Cambridge, MA, United States of America), N. Pandit-Abid (Bridgewater, NJ, United States of America), Y. Deniz (Tarrytown, NY, United States of America), P. Rowe (Bridgewater, NJ, United States of America), B. Ortiz (Tarrytown, NY, United States of America)
| |
Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE
E. Bateman (Cape Town, South Africa), I. Pavord (Oxford, United Kingdom), W. Busse (Madison, United States of America), N. Daizadeh (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), J. Jacob-Nara (Cambridge/Bridgewater, United States of America), R. Gall (Tarrytown, United States of America), N. Pandit-Abid (Bridgewater, United States of America), B. Ortiz (Tarrytown, United States of America)
| |
Late Breaking Abstract - Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
M. Lommatzsch (Rostock, Germany), M. Klein (Rostock, Germany), P. Stoll (Rostock, Germany), J. Virchow (Rostock, Germany)
| |
Discussion
| |